Macomics is an immuno-oncology company with world-leading expertise in macrophage biology, developing precision medicines to modulate macrophages for the treatment of cancer.
The Award, organised by leading trade association One Nucleus, seeks to celebrate life sciences successes from the past year. Specifically, this translational award, organised as part of the On Helix conference in Cambridge, recognises companies that demonstrated success in advancing their programme along the innovation pipeline, be that a new therapeutic, diagnostic or enabling technology.
Stephen Myatt, CEO of Macomics said, “I am delighted Macomics has been voted as winner of this year’s award. This global collaboration with Ono is a testament to our strong program portfolio, and the unique enablement offered by our ENIGMAC discovery platform, and our world class R&D team. Ono is a leader in immuno-oncology and we are delighted to have a partner in Ono who brings the complementary skills necessary to succeed in this therapeutic area.”
You can see the full press release here.
